To explore the association between NCOR1 mutations and the efficacy of ICIs in bladder cancer patients, we used cBioportal to download the ICI-treated bladder cancer cohort (Samstein et al.), including 215 patients receiving ICIs (PD-(L)1 and/or CTLA-4 inhibitors. Here, NCOR1 is linked to urinary bladder cancer.